PureTech Health PLC

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors.

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

BOSTON--(BUSINESS WIRE)--PureTech to Present at CHEST 2024 Annual Meeting.

PureTech to Present at CHEST 2024 Annual Meeting

PureTech Health plc (NASDAQ:PRTC ) Q2 2024 Earnings Conference Call August 28, 2024 9:00 AM ET Company Participants Allison Mead Talbot - Head of Communications Bharatt Chowrira - CEO Eric Elenko - Co-Founder & President Conference Call Participants Lucy Codrington - Jefferies Thomas Smith - Leerink Partners Miles Dixon - Peel Hunt Operator Greetings, and welcome to the PureTech Health 2024 Half Year Results Conference Call. At this time, all participants are in listen-only mode.

PureTech Health plc (PRTC) Q2 2024 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--PureTech Health plc – Half-Year Report.

PureTech Health plc – Half-Year Report

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.

PureTech Health: Notice of Half-Yearly Results

BOSTON--(BUSINESS WIRE)--PureTech Health: Results of the Tender Offer.

PureTech Health: Results of the Tender Offer

BOSTON--(BUSINESS WIRE)--Raju Kucherlapati, PhD, has been appointed Chair of the PureTech Board of Directors.

PureTech Announces Change of Board Role

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team.

PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team

BOSTON--(BUSINESS WIRE)--PureTech Health: Results of AGM.

PureTech Health: Results of Annual General Meeting

BOSTON--(BUSINESS WIRE)--PureTech Health: Result of General Meeting.

PureTech Health: Result of General Meeting

Akili Inc

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive and Virtual Therapeutics Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company.

PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.

PureTech to Present at the Jefferies Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study of VE303.

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

BOSTON--(BUSINESS WIRE)--PureTech Health: Launch of Proposed $100 million Tender Offer at 250 pence per Ordinary Share.

PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting.

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments.

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

PureTech Health plc (NASDAQ:PRTC ) Q4 2023 Earnings Conference Call April 25, 2024 9:00 AM ET Company Participants Allison Mead Talbot - Head, Communications Bharatt Chowrira - Chief Executive Officer Eric Elenko - Co-Founder and President Chip Sherwood - General Counsel Conference Call Participants Miles Dixon - Peel Hunt Lucy Codrington - Jefferies Operator Greetings, and welcome to the PureTech Health 2023 Year End Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2023.

PureTech Announces Annual Results for Year Ended December 31, 2023

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.

PureTech Health: Notice of Results

BOSTON--(BUSINESS WIRE)--PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis.

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

BOSTON--(BUSINESS WIRE)--PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers.

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

BOSTON--(BUSINESS WIRE)--PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions.

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

PureTech Health (PRTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

PureTech Health (PRTC) is on the Move, Here's Why the Trend Could be Sustainable

PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's lead asset, LYT-100, may be a promising treatment for idiopathic pulmonary fibrosis (IPF) with a better tolerability profile compared to standard of care drugs.

PureTech Health: Repeat What Works

Bristol-Myers

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded Entity, Karuna Therapeutics, Inc. ("Karuna”), by Bristol Myers Squibb (NYSE: BMY) (“BMS”), which has acquired all outstanding common stock of Karuna for $330.00 per share, for a total equity value of approximately $14 billion. "This acquisition recognizes the enormous potential of KarXT to help mi.

News for PureTech Health PLC Stock (PRTC)